Aastrom Enrolls First Patients In Phase 2b Clinical Trial of Ixmyelocel-TAastrom Biosciences Inc. (Nasdaq:ASTM), the developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that the first patients have been enrolled in the ixCELL-DCM clinical trial.
Aastrom To Refocus Research On Dilated Cardiomyopathy, Cut StaffAastrom Biosciences Inc., a developer of patient-specific expanded multicellular therapies for the treatment of severe chronic diseases, announced a strategic change in its research and development programs to focus on the clinical development of its lead product, ixmyelocel-T, for the treatment of dilated cardiomyopathy.
Aastrom Board Names Dominick C. Colangelo President, CEOAastrom Biosciences Inc. announced that the company’s board of directors has named Dominick C. Colangelo as president and CEO.
Stem Cell Therapy Could Offer New Hope For Head, Mouth Injuries, DefectsIn the first human study of its kind, researchers found that using stem cells to re-grow craniofacial tissues -- mainly bone -- proved quicker, more effective and less invasive than traditional bone regeneration treatments.

More From CBS Detroit

Daily J
Valenti and Foster

Watch & Listen